In a filing, Keros Therapeutics Inc revealed its Director GORDON CARL L unloaded Company’s shares for reported $11.0 million on Aug 13 ’24. In the deal valued at $44.01 per share,250,000 shares were sold. As a result of this transaction, GORDON CARL L now holds 119,522 shares worth roughly $6.77 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ORBIMED ADVISORS LLC sold 250,000 shares, generating $11,002,500 in total proceeds. Upon selling the shares at $44.01, the Director now owns 119,522 shares.
Before that, OrbiMed Genesis Master Fund, L bought 29,400 shares. Keros Therapeutics Inc shares valued at $1,318,296 were divested by the Shareholder at a price of $44.84 per share.
Jefferies initiated its Keros Therapeutics Inc [KROS] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late October with a ‘”an Overweight”‘ rating. Scotiabank began covering KROS with “Sector outperform” recommendation on October 16, 2024. Guggenheim started covering the stock on September 23, 2024. It rated KROS as “a Buy”.
Price Performance Review of KROS
On Friday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -6.18% to $56.62. Over the last five days, the stock has lost -16.62%. Keros Therapeutics Inc shares have risen nearly 42.40% since the year began. Nevertheless, the stocks have risen 77.71% over the past one year. While a 52-week high of $73.00 was reached on 02/29/24, a 52-week low of $27.31 was recorded on 01/02/24. SMA at 50 days reached $59.41, while 200 days put it at $55.41.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 54.39, which if violated will result in even more drops to 52.17. On the upside, there is a resistance level at 59.71. A further resistance level may holdings at 62.81. The Relative Strength Index (RSI) on the 14-day chart is 38.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.48, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.93%. Stochastics %K at 24.91% indicates the stock is a holding.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2024-10-31, dropping by -0.61 million shares to a total of 2.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.02 million shares. There was a decline of -25.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 25, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $102 price target.
